The Stedman Center on the Duke Center for Living Campus — Durham, North Carolina

The Stedman Center on the Duke Center for Living Campus is a clinical research site located in Durham, North Carolina, United States 27705.

Crixeo Clinical Trials Trust Score: 11/100 (FAILING). This profile has not yet been claimed by the site owner.

The Stedman Center on the Duke Center for Living Campus has participated in 2 clinical trials.

Therapeutic areas: Multiple Sclerosis, Primary Progressive Multiple Sclerosis.

Sponsors: Duke University.

Is this your site?

Is this your site? Claim your profile and control the information sponsors and patients see.

Other research sites in Durham

Browse all research sites in North Carolina · View every site in Durham

Sponsor Feasibility Report

Trust Score: 11/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for The Stedman Center on the Duke Center for Living Campus?

The Stedman Center on the Duke Center for Living Campus has a Crixeo Trust Score of 11/100 (FAILING). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has The Stedman Center on the Duke Center for Living Campus conducted?

The Stedman Center on the Duke Center for Living Campus has 2 clinical trials on record. Their work covers Multiple Sclerosis, Primary Progressive Multiple Sclerosis.

Is The Stedman Center on the Duke Center for Living Campus accredited by Crixeo Clinical Trials?

The Stedman Center on the Duke Center for Living Campus has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about The Stedman Center on the Duke Center for Living Campus?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.